SA PRO
Free Account
CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 60% recommend buying.

Consensus Rating
Buy
25 analysts·High coverage
60%
Rating Distribution
Strong Buy
00%
Buy
1560%
Hold
832%
Sell
28%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 33% higher.

Bear Case
$50.00
+0%
Consensus
$66.33
+33%
Bull Case
$75.00
+50%
Price Range25 analysts
Low
Consensus
High
$50.00
$75.00
Current Target
Current Price
$49.96
Upside to Target
$16.37

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Nov 26, 2025Chardan Capital
Crispr Therapeutics price target lowered to $74 from $82 at Chardan
Target:$74.00
+40.2%from $52.79
Nov 11, 2025RBC Capital
CRISPR Therapeutics (CRSP) PT Raised to $50 at RBC Capital
Target:$50.00
-8.4%from $54.58
Oct 13, 2025Wells Fargo
Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo
Target:$75.00
+2.6%from $73.09
Feb 3, 2025H.C. Wainwright
Crispr Therapeutics initiated with a Buy at H.C. Wainwright
Target:$65.00
+62.5%from $40.00
Nov 6, 2024Oppenheimer
Oppenheimer Reiterates Outperform Rating on CRISPR Therapeutics (CRSP)
Target:$95.00
+91.9%from $49.51
Nov 5, 2024Leerink Partners
CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners
Target:$67.00
+33.0%from $50.36
Aug 12, 2024Truist Financial
Crispr Therapeutics price target lowered to $100 from $120 at Truist
Target:$100.00
+114.8%from $46.55
Aug 6, 2024Needham
CRISPR Therapeutics (CRSP) PT Lowered to $84 at Needham
Target:$84.00
+67.6%from $50.11
Aug 6, 2024Stifel Nicolaus
CRISPR Therapeutics (CRSP) PT Lowered to $59 at Stifel
Target:$59.00
+18.0%from $50.01
Aug 6, 2024RBC Capital
CRISPR Therapeutics (CRSP) PT Lowered to $60 at RBC Capital
Target:$60.00
+19.7%from $50.13
May 9, 2024Robert W. Baird
CRISPR Therapeutics (CRSP) PT Raised to $52 at Baird
Target:$52.00
-2.4%from $53.29
Nov 23, 2022Citigroup
Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $63
Target:$63.00
+13.1%from $55.72
Aug 9, 2022Chardan Capital
NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday
Target:$79.30
-2.6%from $81.39
Jun 17, 2022BMO Capital
3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner
Target:$98.00
+38.6%from $70.73
Apr 28, 2022Credit Suisse
Credit Suisse Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $78
Target:$78.00
+50.1%from $51.96
Feb 16, 2022Needham
Needham Thinks Crispr Therapeutics AG's Stock is Going to Recover
Target:$170.00
+174.3%from $61.97
Feb 15, 2022Leerink Partners
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (NASDAQ: AMRN), Crispr Therapeutics AG (NASDAQ: CRSP) and Allakos (NASDAQ: ALLK)
Target:$120.00
+96.8%from $60.97
Jan 7, 2022Wells Fargo
Wall Street Analysts Are Neutral on Top Healthcare Picks
Target:$105.00
+55.2%from $67.66
Nov 4, 2021Oppenheimer
Crispr Therapeutics price target lowered to $172 from $185 at Oppenheimer
Target:$172.00
+84.9%from $93.00
Oct 12, 2021Piper Sandler
Piper Sandler says buy Crispr Therapeutics on weakness
Target:$180.00
+75.5%from $102.59
Aug 16, 2021Canaccord Genuity
Crispr Therapeutics price target raised to $160 from $151 at Canaccord
Target:$160.00
+30.6%from $122.55
Jun 11, 2021Roth Capital
Crispr Therapeutics (CRSP) reported robust sickle cell data, says Roth Capital
Target:$171.00
+34.6%from $127.00
Apr 21, 2021Jefferies
Crispr Therapeutics Is Upgraded After $900 Million Deal
Target:$172.00
+37.7%from $124.93

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance